Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The lipopeptide daptomycin has been approved for use in skin and skin-structure infections but has failed to meet statistical noninferiority criteria in a clinical trial for severe community-acquired pneumonia. Daptomycin exhibited an unusual pattern of activity in pulmonary animal models: efficacy in Staphylococcus aureus hematogenous pneumonia and inhalation anthrax but no activity against Streptococcus pneumoniae in simple bronchial-alveolar pneumonia. Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in inhibition of antibacterial activity. This effect was specific to daptomycin and consistent with its known mechanism of action. This represents the first example of organ-specific inhibition of an antibiotic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daptomycin is inhibited by pulmonary surfactant 160 and thus is contraindicated in the treatment of S aureus pneumonia acquired via the aspiration route.”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Pulmonary surfactant: functions and molecular composition
Goerke, J. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00060-x · Cited by 724 · cited 3×
“pulmonary surfactant is different from that of most eukaryotic membranes; it primarily contains PC and only low levels of cholesterol and sphingolipids [3].”
BackgroundInfluentialCorrelation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656 · cited 2×
“molecular synthesis, and cell death [7].”
BackgroundSelf-citationIn Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundCarpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358 · cited 1×
“class of antibiotics, the lipopeptides [6].”
Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin
Jung, D., Rozek, A., Okon, M., & Hancock, R. E. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.020 · Cited by 297 · cited 3×
“Daptomycin is inserted into the membrane of gram-positive bacteria and artificial lipid vesicles [7, 15, 16].”
BackgroundPenetration of Antibiotics into Respiratory Secretions
Pennington, J. E. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.67 · Cited by 192
Extraction, Characterization, and Cellular Localization of the Lipids of Staphylococcus aureus
White, D. C., & Frerman, F. E. (1967) · Journal of Bacteriology · doi:10.1128/jb.94.6.1854-1867.1967 · Cited by 184 · cited 1×
“Surfactant is also ∼10% PG, a prominent component of the gram-positive plasma membrane [18].”
BackgroundSakoulas, G., Eliopoulos, G. M., Alder, J. D., & Eliopoulos, C. T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1714-1718.2003 · Cited by 133 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundSelf-citation
Cited by
Items 501–548 of 548
Suzaki, A. (2013) · Journal of Nihon University Medical Association · doi:10.4264/numa.72.167
Resistance ofMycobacterium tuberculosisto daptomycin
Moon, C., & Jang, J. (2016) · Scandinavian Journal of Infectious Diseases · doi:10.3109/23744235.2016.1164340
“Thus, the currently available experimental and clinical data for mice and humans suggest that daptomycin has at least small efficacy against Gram-positive bacterial infections of the lung.[6] Recently, Bastian et al.”
BackgroundDaptomycin: studies on its action mode and on bacterial resistance with model membranes
Scott, B. (2016) · UWSpace (University of Waterloo)
A Case of Ventilator-Associated Pneumoniae Complicated with Antibiotics-induced Severe Drug Eruption
Matsunaga, N., Suda, S., Hatanaka, E., Ikeda, T., Ueno, T., & Okuyama, K. (2015) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.41.651
Daptomycin zur Behandlung grampositiver Infektionen nach herzchirurgischen Eingriffen
von Gœthe, J. W., & Kai, T. (2013)
Lee, B. (2017) · UWSpace (University of Waterloo) · Cited by 1
López-Rivera, F., Monroig, H. A. G., Eggert, J., Cintrón‐Colón, H. R., Díaz, J. C., Meléndez, O. M., & Abreu, F. (2017) · Case Reports International · doi:10.5348/crint-2017-42-cr-10
“Another type of anti-MRSA antibiotic, daptomycin, should not be prescribed in patients with pneumonia because it is inhibited by pulmonary surfactant [11].”
Background(2012) · Wiley eBooks · doi:10.1002/9781118325421.ch16
Daptomycin in the treatment of infective endocarditis
Попов, Д. А. (2018) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2018.1.35-40
CLINICAL CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH INFECTIVE ENDOCARDITIS (IE)
Syed, I. (2018) · TSpace (University of Toronto)
Precision Drug Delivery for Vancomycin Efficacy and Safety in Critically Ill Patients
Flannery, A. H. (2021) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2021.066
Role of sparsity in high dimensional signal detection and estimation
Saligrama, V., & Zhao, M. (2011)
Staphylococcus aureus Bacteremia and Endocarditis
Kanafani, Z. A., Cosgrove, S. E., & Fowler, V. G. (2009) · Wiley eBooks · doi:10.1002/9781444308464.ch16
(2005) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)00084-x
Hudcova, J., Craven, K. A., & Craven, D. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-19668-8_30 · Cited by 1
Smith, J. R., Claeys, K. C., Zasowski, E. J., Yim, J., & Rybak, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_21
Protocolo de tratamiento empírico de la neumonía nosocomial y asociada a ventilador
de Santiago, A. D., Díaz, A. C., & Serrano, A. M. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.03.008
Gunasingha, R. M. K. D., Benoit, P., & Bradley, M. J. (2022) · Wiley eBooks · doi:10.1002/9781119756781.ch9
Orak, F. (2015) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2015.78309
Bourguignon, L., & Goutelle, S. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-75300-8.00012-4
Antibiotics for bacteraemia due to Staphylococcus aureus
Karanth, V. K., Karanth, S. K., & Karanth, L. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011465
RetractedRighetto, G. M. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.76.2022.tde-17082022-093412
Behandlung von Staphylococcus-aureus-Blutstrominfektionen: Etabliertes und neue Entwicklungen
Schellong, P., Hagel, S., Pletz, M. W., & Weis, S. (2022) · Zeitschrift für Pneumologie · doi:10.1007/s10405-022-00473-x
Antibiotika, Antibiotikaprophylaxe und Antimykotika in der Intensivmedizin
Wetzstein, N., Vehreschild, J. J., & Vehreschild, M. J. G. T. (2023) · Springer Reference Medizin · doi:10.1007/978-3-642-54675-4_82-2
Ogunniyi, A. D., Hang, N. T. T., Hansford, K. A., Cooper, M. A., Trott, D. J., & Blaskovich, M. A. T. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04459-22
“The use of daptomycin to treat pneumococcal pneumonia is also not recommended due to its inactivation by lung surfactants (9).”
Backgroundde Lima, I. A. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.76.2024.tde-23042024-113433 · Cited by 1
Antibiotika, Antibiotikaprophylaxe und Antimykotika in der Intensivmedizin
Wetzstein, N., Vehreschild, J. J., & Vehreschild, M. J. G. T. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-68699-7_82
Antibiotic-Resistant Pathogens in Ear, Nose, and Throat Infections
Brook, I. (2024) · Springer eBooks · doi:10.1007/978-3-031-68449-4_2
The Pharmacokinetic-Pharmacodynamic Interface
Goldman, J. L., Dinh, J., & Abdel‐Rahman, S. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00251-x
Enterococcal and Viridans Streptococcal Infections
McNeil, J. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00084-4
Machhua, P., Unnithan, V. G., Liu, Y., Jiang, Y., Zhang, L., & Guo, Z. (2025) · eLife · doi:10.7554/elife.93267.3.sa2
Cimato, A. N., Degrossi, J., Facorro, G. B., & Sarrasague, M. M. (2025) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2025.104503
Bilgin, Z. D., & Toker, S. E. (2025) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2025.2589466
Genomic analysis of diverse bacterial pathogens
Potter, R. (2020) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/0sep-5b13
Zhang, Y., & Yi, L. (2026) · American Journal of Case Reports · doi:10.12659/ajcr.951333
“This pharmacokinetic limitation may explain the progression of septic pulmonary embolism in our patient despite temporary bacteremia clearance [18].”
Lefevre, S. (2012) · theses.fr (ABES) · doi:10.70675/ea7bb4a2z7983z45c8zaecazee2a7f6b34be
“Des études in vitro ont montré que la daptomycine est séquestrée dans le surfactant pulmonaire bovin entr aînant une inhibition de son activité antibactérienne (168).”
BackgroundCaractérisation d’un système de résistance aux peptides antimicrobiens chez Streptococcus pneumoniae
Faure, A. (2023) · theses.fr (ABES) · doi:10.70675/f2d4f567z79a6z4f03zbbafz261d267eb749
Moreal, C., Angelini, J., Pai, M. P., Giuliano, S., & Tascini, C. (2026) · Academia Drug Development and Pharmacotherapy · doi:10.20935/acaddrug8303
Li, X., Zhu, Y., Huang, F., Jiang, Y., & Zhou, L. Y. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s624501
“12 Cefazolin 1.0 g q6h was then introduced as MSSA-directed beta-lactam therapy after reassessment of susceptibility and clinical status.”
InfluentialHamelin, T. J., Molaeitabari, A., Mackinnon, M. R., Dahms, T. E. S., & El-Halfawy, O. M. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6c00319
Crocoll, S., Forßmann, L., Munz, L., Häcker, G., Bechthold, A., & Heerklotz, H. H. (2026) · Biophysical Journal · doi:10.1016/j.bpj.2026.09.004
Antimicrobial Peptides Beyond the Petri Dish: Translational Barriers to Therapeutic Development
Torrent, M. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.6c00126
Lalbiaktluangi, C., Singh, A., Vidal, A. G. J., Singh, J., Kant, K., Vellingiri, B., Iyer, M., Singh, P. K., Ram, H., Kharat, A., et al. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108840
Akhtar, A., Zameer, S., Hasan, M. Y., Alam, M., Abbas, K., Faraz, M., Khan, F., & Fatima, N. (2026) · Discover Medicine · doi:10.1007/s44337-026-00698-2
“As a result, daptomycin efficacy is compromised in bronchial-alveolar pneumonia, observing its clinical ineffectiveness in pneumonia treatment [10].”
Medina-Salinas, G. E., Chirinos-Castillo, J. J., & Castillo-Stark, L. Z. (2026) · CIENCIAMATRIA · doi:10.35381/cm.v12i6.3377
Wang, J., Li, Y., Zhang, Y., Wang, D., Liu, Y., Song, Y., & Li, Y. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100671
Toplumdan Kazanılmış Metisiline Dirençli S. aureus
Güneş, H., & Çetin, E. S. (2012) · Acibadem Universitesi Saglik Bilimleri Dergisi · Cited by 1
Metadata
- Authors
- Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J.
- Affiliations
- Cubist Pharmaceuticals (United States) (US)
- Corresponding author
- Silverman, Jared A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-15
- Volume
- 191
- Issue
- 12
- Pages
- 2149-2152
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2108525727
- Cited by
- 541
- References
- 18
- Citations by year
- 2026: 17 · 2025: 14 · 2024: 25 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 18 · 2019: 20 · 2018: 24 · 2017: 24 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 28
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Keywords
- daptomycin, pulmonary surfactant, antibiotic inhibition, lipopeptide antibiotics, Staphylococcus aureus, Streptococcus pneumoniae, community-acquired pneumonia, inhalational anthrax, antibiotic-drug interactions
- MeSH terms
- Animals, Anti-Bacterial Agents, Lung, Microbial Sensitivity Tests, Pneumococcal Infections, Pulmonary Surfactants, Staphylococcal Infections, Daptomycin, Pneumonia, Bacterial, Drug Resistance, Bacterial, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.